NDAORALTABLET
Approved
Dec 1996
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZAGAM (sparfloxacin) is an oral fluoroquinolone antibiotic approved in 1996 for bacterial infections. It is a broad-spectrum agent used to treat respiratory and other bacterial infections via systemic absorption. The drug works by inhibiting bacterial DNA gyrase and topoisomerase IV, disrupting DNA replication.
LOE Approaching
As LOE approaches, the brand team is likely focused on lifecycle extension and generic transition planning; team size may be declining.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on ZAGAM offers limited upside career opportunity given its LOE-approaching status and minimal linked job openings. This role is best suited for professionals managing mature asset transitions, optimizing generic conversion, or gaining foundational commercial experience.
Brand ManagerField Sales Representative
Worked on ZAGAM at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.